We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
171 hedge funds and large institutions have $4.39B invested in Puma Biotechnology in 2017 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
41% more capital invested
Capital invested by funds: $3.1B → $4.39B (+$1.29B)
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
18% more call options, than puts
Call options by funds: $87.1M | Put options by funds: $74M
11% more funds holding
Funds holding: 154 → 171 (+17)
2.49% more ownership
Funds ownership: 96.09% → 98.59% (+2.5%)
Holders
171
Holders Change
+17
Holders Change %
+11.04%
% of All Funds
4.26%
Holding in Top 10
12
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+100%
% of All Funds
0.3%
New
42
Increased
62
Reduced
48
Closed
25
Calls
$87.1M
Puts
$74M
Net Calls
+$13.2M
Net Calls Change
+$8.88M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$170M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$61.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$37.5M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$33.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.6M |
